Addendum

Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18

Status
Status: Commission completed
Project no.
A21-85
Last updated

Report documents

  1. Addendum

    Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18

    published on
    Document type
    PDF document, 296 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with asthma whose disease is not adequately controlled with a combination of medium- or high-dose ICS and LABA, and who experienced one or more asthma exacerbations in the previous year

Result of dossier assessment:

Unchanged after addendum:

  • Medium-dose ICS/LABA therapy: added benefit not proven.
  • High-dose ICS/LABA therapy: added benefit not proven.

Additional information

Federal Joint Committee (G-BA)

19 December 2024: The G-BA’s decision of 5 August 2021 was cancelled.

G-BA documents on this decision

Project details

Project no.
A21-85
Commission
Commission awarded on 22.06.2021 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Airways and respiratory system
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-18
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form